middle.news
Recce Pharmaceuticals Advances RECCE® 327 with Promising Phase II Topical Gel Results
9:57am on Tuesday 21st of January, 2025 AEDT
•
Pharmaceuticals
Read Story
Recce Pharmaceuticals Advances RECCE® 327 with Promising Phase II Topical Gel Results
9:57am on Tuesday 21st of January, 2025 AEDT
Key Points
All 30 patients dosed in Phase II trial of RECCE® 327 topical gel for ABSSSI
Preliminary data shows complete cure or significant symptom improvement with no serious adverse events
Full Phase II results expected in Q1 2025 after Data Safety Monitoring Board review
Phase III registrational trials planned in Australia (H1 2025) and Indonesia for diabetic foot infections
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE